AHP's Wyeth-Ayerst in co-promotion with King
Executive Summary
AHP's Wyeth-Ayerst Laboratories unit licensed co-promotion rights in the US and Puerto Rico to King Pharmaceuticals' (acquires or develops branded pharmaceuticals and sells them) cardiovascular and hypertension drug Altace (ramipril) for an eight-year term (automatically extendible if King gets additional patents or exclusivity on the drug). In return, AHP is turning over US and Puerto Rican rights to its oral contraceptive Nordette (levonorgestrel, ethinyl oestradiol) and two other undisclosed products for $200mm (of which AHP loaned King $25mm).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Product or Technology Swap
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice